Metabolic profile and autonomic and cardiovascular recovery in hypertensive individuals under the acute effect of resveratrol

Acute effect of resveratrol on the metabolic profile and on autonomic and cardiovascular recovery in individuals with non-communicable chronic diseases

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-9qv5gd7

Enrollment

Unknown

Registered

2025-10-05

Start date

2025-08-03

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

This is a randomized, double-blind, crossover, placebo-controlled clinical study. A total of 25 volunteers will be allocated to the following treatment protocols: Protocol I) Placebo (600 mg of starch

G07.203.300.456

Eligibility

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Volunteers must be between 18 and 59 years of age. There will be no gender restrictions, however, study participants will be allocated to different groups based on male or female gender. Participants must not have skeletal muscle injuries

Exclusion criteria

Exclusion criteria: Patients with cardiorespiratory, neurological and other known impairments that prevent the subject from performing the procedures. Women will not be included in the period of 10-15 days and 20-25 days after the first day of the menstrual cycle to avoid influence of the luteal and follicular phases of the menstrual cycle. Participants will be instructed not to drink alcoholic beverages or consume substances containing resveratrol (for example, teas, açaí, chocolate, whole grape juice, red or white wine and soft drinks). Do not perform high-intensity training for 24 hours prior to the evaluation. Consumption of grape juice, caffeine, alcoholic beverages or any other type of substance prior to the procedure

Design outcomes

Primary

Measure	Time frame
Resveratrol supplementation is expected to improve autonomic and cardiovascular recovery, with an increase of at least 15% in heart rate variability, measured in milliseconds (ms) in individuals with systemic arterial hypertension;Reduction in blood pressure of at least 5 mmHg in systolic blood pressure and 3 mmHg in diastolic blood pressure after acute consumption of resveratrol in hypertensive patients	—

Measure

Time frame

Resveratrol supplementation is expected to improve autonomic and cardiovascular recovery, with an increase of at least 15% in heart rate variability, measured in milliseconds (ms) in individuals with systemic arterial hypertension;Reduction in blood pressure of at least 5 mmHg in systolic blood pressure and 3 mmHg in diastolic blood pressure after acute consumption of resveratrol in hypertensive patients

—

Secondary

Measure	Time frame
No secondary outcomes are expected	—

Countries

Brazil

Contacts

Public ContactAnny Micaeli Macêdo Sousa Santana Campus Petrolina

Universidade de Pernambuco

anny.mmsousa@upe.br+55 (87) 38666468

Outcome results

None listed

Source: REBEC (via WHO ICTRP)